BIM
IMDX

BlackRock Investment Management’s Insight Molecular Diagnostics IMDX Stock Holding History

BlackRock Investment Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$5K Hold
36
– – ﹤0.01% 3767
2016
Q3 		$4K Buy
36
+13
+57% +$1.05K ﹤0.01% 3812
2016
Q2 		$2K Sell
23
-453
-95% -$42.3K ﹤0.01% 3982
2016
Q1 		$44K Buy
+476
New +$42.2K ﹤0.01% 3284

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FM
Family Management New York $834M AUM 20.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Investment Management's IMDX Position: Q4 2016 in Review

BlackRock Investment Management held its Insight Molecular Diagnostics (IMDX) position steady in Q4 2016 at 36 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #3767.

BlackRock Investment Management first reported a position in IMDX in Q1 2016 and has held it in 4 quarters since. The position peaked at $44K in Q1 2016. 32 funds tracked by Wall St. Rank hold IMDX as of Q4 2016.

  • BlackRock Investment Management held 36 shares of Insight Molecular Diagnostics worth $5K as of Q4 2016.
  • BlackRock Investment Management left its Insight Molecular Diagnostics share count unchanged in Q4 2016.
  • Insight Molecular Diagnostics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3767 holding.
  • BlackRock Investment Management first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 4 quarters since.
  • BlackRock Investment Management's Insight Molecular Diagnostics position peaked at $44K in Q1 2016.
  • 32 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.